# Does Alabama Medicaid Cover Wegovy or Zepbound? The Three PA Routes By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06 Canonical page: https://glpwatchdog.org/research/alabama-medicaid-glp1-coverage > Alabama Medicaid refuses every GLP-1 for weight loss. Its October 2026 drug list and Form 369 instructions still open three routes: Zepbound when sleep apnea is present, and Wegovy for existing heart disease or MASH. Criteria, the diabetes catch, Xenical and appeals. ## Key points - Weight loss alone is not covered: the state drug list marks both Wegovy and Zepbound non-covered for weight reduction. - Zepbound is a preferred drug for sleep apnea, with an AHI of 15 or more, a BMI of 30 or more and no CPAP step. - Wegovy needs prior authorization for heart disease at a BMI of 27 or more, or for MASH with F2 to F3 fibrosis. - The sleep apnea and MASH routes exclude people with diabetes, who use the diabetes criteria instead. - Xenical is the one weight-loss drug with its own criteria, and a fair hearing request is due within 60 days of the notice. No. As of November 2026, Alabama Medicaid does not cover Wegovy, Zepbound or any other GLP-1 for weight loss; its drug list calls both drugs “non-covered for weight reduction.”[1] It does pay for three narrower uses with prior authorization: Zepbound for moderate to severe sleep apnea, and Wegovy to lower heart risk or to treat the liver disease MASH, in each case for adults who meet the state’s criteria.[1][2] > **About this article.** This page reads the Alabama Medicaid Agency’s preferred drug list and its prior authorization instructions, both effective October 1, 2026, as they stood on November 6, 2026. Alabama updates the drug list each quarter, so check the current file before filing. For how every state compares, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Will Alabama Medicaid pay for a GLP-1 to lose weight? It does not. The GLP-1 section of the state’s drug list carries two footnotes that settle the question. The Zepbound note rules out weight reduction “without OSA,” and the Wegovy note rules it out with no sleep apnea exception at all.[1] The same footnotes appear on the January 2026 list, so this has been the rule all year.[10] Under federal law, every state may make that choice. Drugs used for weight loss sit on a short list of medicines a Medicaid program may leave out, alongside fertility and cosmetic drugs.[5] Alabama uses the option for GLP-1s but not for every weight-loss drug, as the section on Xenical below shows. Our explainer on [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal side in more depth. ## When does Alabama Medicaid pay for a GLP-1? In four situations. Type 2 diabetes is the broad one, and the other three are the uses the FDA has added to the Wegovy and Zepbound labels beyond weight.[6][7] Since October 2026 the state groups those three under one heading in its instructions, “Incretin Mimetics for Non-Diabetes Indications.”[2] *Alabama Medicaid GLP-1 rules by use, from the drug list and Form 369 instructions effective October 1, 2026* | Use | Drug | Status | Main requirements | | --- | --- | --- | --- | | Weight loss alone | Wegovy, Zepbound | Not covered | No route | | Type 2 diabetes | Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza, Byetta | Preferred, with clinical criteria | Diabetes diagnosis; failed 30-day trials of two preferred diabetes drugs in the past year, or a reason they cannot be used | | Moderate to severe sleep apnea | Zepbound | Preferred, with clinical criteria | Adults only; 15 or more breathing events an hour on a sleep study; BMI 30 or higher; no diabetes; diet and activity counseling; no other GLP-1 | | Reducing heart attack and stroke risk | Wegovy | Non-preferred, PA required | Adult with established heart disease; BMI of at least 27 | | MASH with F2 to F3 fibrosis | Wegovy | Non-preferred, PA required | Documentation of the MASH diagnosis; adult with overweight or obesity; no diabetes | Two details in the instructions deserve a careful read. The sleep apnea and MASH bullets each say “no diagnosis of diabetes,” so a person with diabetes is steered to the diabetes route, where Mounjaro, the same drug as Zepbound, is already a preferred choice.[1][2] The heart bullet in the October text does not repeat that phrase.[2] And the MASH bullet leaves a door open below the usual weight line: a request with a BMI under 27 can still be considered with “appropriate documentation.”[2] ## What does Alabama require for Zepbound and sleep apnea? Zepbound has an unusual standing here. It sits in the preferred column of Alabama’s list while Wegovy does not, but only for sleep apnea with obesity.[1] The patient must be 18 or older, with sleep apnea rated moderate to severe, an AHI (apnea-hypopnea index) score from 15 up, and a BMI from 30 up.[2] The prescriber also confirms that the patient has been counseled on diet and activity and is not on a second GLP-1.[2] What the instructions leave out matters as much. They set no CPAP trial and name no sleep specialist.[2] That keeps Alabama close to the Zepbound label, whose sleep apnea use is limited to adults who also have obesity.[6] Renewal is where sleep apnea differs from the other routes: instead of weight records, the prescriber can show better sleep, either on a sleepiness scale such as the Epworth or on a repeat sleep study.[2] Our guide to [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) explains the trials behind that indication. ## Will Alabama Medicaid cover Wegovy for heart disease or fatty liver? Yes, through prior authorization, although Wegovy is a non-preferred drug.[1] For the heart route the request must document established cardiovascular disease in an adult with a BMI of 27 or more.[2] That matches the label, which covers adults with heart disease and either obesity or overweight.[7] The MASH route covers adults with noncirrhotic disease and moderate to advanced fibrosis, stages F2 to F3, the same wording as the label.[2][7] Alabama’s text asks for documentation that supports the diagnosis but, unlike some states, does not list a required test or a liver specialist.[2] A biopsy report or a liver stiffness result still makes the strongest file. The FDA approved this use on an accelerated basis, and our page on [GLP-1s and MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers what the trial showed.[7] ## How long does an approval last, and how do you renew it? The first approval for any of the three non-diabetes uses lasts up to six months, and renewals can run up to 12 months.[2] Heart and MASH renewals need weight records from the past 90 days showing adequate loss; sleep apnea renewals can use the sleep evidence described above instead.[2] Diabetes approvals can run up to 12 months from the start.[2] How the request travels matters too. Diabetes drugs run through the state’s electronic prior authorization program, which can clear a claim from the pharmacy record, but the three non-diabetes uses are excluded from it and cannot be requested by phone.[2] The prescriber files Form 369 with Acentra Health, the agency’s prior authorization contractor, by fax at 1-800-748-0116; the help line is 1-800-748-0130.[2][3] ## Does Alabama Medicaid cover any weight-loss drug? One. Xenical (orlistat) has its own prior authorization criteria, starting at age 12, for a BMI of 27 or more with diabetes, high blood pressure or high cholesterol.[2] The request must show at least six months of a physician-supervised diet and exercise program that did not work, and renewals need continued weight loss.[2] Orlistat produces far smaller losses than a GLP-1; our review of orlistat and Alli sets out the evidence. ## How do you appeal a denial in Alabama? Start with the reason on the notice. A denial for missing paperwork, such as no sleep study or no BMI on file, is often fixed by resubmitting with the record. An appeal has little to argue if the only diagnosis is obesity, because no route exists for that.[1] For a formal appeal, Alabama’s rule requires the written fair hearing request to reach the agency within 60 days of the date the notice was mailed, and late requests are refused.[4] Count from the mailing date on the notice, not the day it arrived. Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to put in the file, and the [Alabama state page](https://glpwatchdog.org/states/alabama) collects the same Medicaid facts in brief. ## What can you do if Alabama Medicaid will not pay? Cash is the main option, and the manufacturer copay cards will not help: Lilly’s savings card terms exclude anyone enrolled in Medicaid.[8] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses through Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound KwikPen.[8][9] Read each offer’s terms on government coverage before enrolling. Our list of the [cheapest GLP-1 routes without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares them. ## Frequently asked questions ### Does Alabama Medicaid cover Wegovy for weight loss? No. Alabama Medicaid's drug list says Wegovy is non-covered for weight reduction. As of November 2026 a prior authorization can still approve it for two other uses: cutting heart risk for an adult with existing cardiovascular disease whose BMI is 27 or above, and treating MASH with F2 to F3 liver fibrosis. ### Does Alabama Medicaid cover Zepbound? Only for sleep apnea. Zepbound is a preferred drug with clinical criteria when an adult has moderate to severe obstructive sleep apnea, an AHI score from 15 up, obesity at a BMI from 30 up, and no diabetes on record. Without sleep apnea it is not covered for weight loss. ### Does Alabama Medicaid cover Ozempic? Yes, for type 2 diabetes. Ozempic is a preferred drug with clinical criteria, which include failed 30-day trials of two preferred diabetes drugs in the past year or a documented reason they cannot be used. It is not covered for weight loss. ### Does Alabama Medicaid require CPAP before approving Zepbound for sleep apnea? No. The October 2026 instructions want an adult patient, an AHI score from 15 up, a BMI from 30 up, no diabetes, diet and activity counseling and no second GLP-1. No CPAP trial appears in the list. ### How long do I have to appeal an Alabama Medicaid denial? Alabama's rule says the written fair hearing request must reach the Medicaid agency within 60 days of the date the notice of action was mailed. Requests received after that are not accepted, so count from the mailing date printed on the notice. ## References 1. Alabama Medicaid Agency Preferred Drug List (PDL) Reference Tool, effective October 1, 2026. almedicaid.acentra.com. 2026. https://almedicaid.acentra.com/wp-content/uploads/sites/16/2026/10/PDL-Tool-Oct-26.pdf 2. Alabama Medicaid Agency, Division of Pharmacy Services Prior Authorization (PA) Criteria Instructions for Form 369, effective October 1, 2026. almedicaid.acentra.com. 2026. https://almedicaid.acentra.com/wp-content/uploads/sites/16/2026/10/PA-Instructions-Oct-26.pdf 3. Acentra Health Alabama Medicaid pharmacy prior authorization: contact details and forms. almedicaid.acentra.com. 2026. https://almedicaid.acentra.com/ 4. State of Alabama Ala. Admin. Code r. 560-X-3-.03: Fair Hearing Procedures for Recipients and Providers. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/alabama/Ala-Admin-Code-r-560-X-3-.03 5. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 6. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 7. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 8. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 9. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html 10. Alabama Medicaid Agency Preferred Drug List (PDL) Reference Tool, January 2026. almedicaid.acentra.com. 2026. https://almedicaid.acentra.com/wp-content/uploads/sites/16/2026/01/PDL-Tool-Jan-26.pdf --- Cite as: GLP Watchdog, Nora Bissett, "Does Alabama Medicaid Cover Wegovy or Zepbound? The Three PA Routes", published 2026-11-06. https://glpwatchdog.org/research/alabama-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/alabama-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.